Bayer is nearing the end of the road for glyphosate, executives say

Bayer is signaling it has had enough of litigation, leaving the future of a crop protection tool in limbo.

Executives tell the Wall Street Journal they are nearing the end of the road for glyphosate, the main ingredient in RoundUp. CEO Bill Anderson says they are barely breaking even, and litigation costs often put them in the red.

More than 65,000 cases are pending against Bayer right now, and the company has around $16 billion set aside for settlements.

Anderson stands by glyphosate, saying it has been proven safe to use, even by the FDA. Bayer produces roughly 40 percent of the supply used by U.S. farmers.

Related Stories

LATEST STORIES BY THIS AUTHOR:

Rising federal debt is increasing pressure on Washington to limit spending, which could tighten future funding and delivery for agricultural programs.
“I’m not sure where this bridge goes,” trader Brady Huck with Advanced Trading told RFD-TV News earlier this week.
CoBank’s 2026 Year Ahead Report cites global grain oversupply, easing inflation, rate cuts, and major data center growth that could reshape rural America.
Plan for sharp, short-term volatility after unexpected outages; permanent closures rarely trigger major price spread disruptions.